Introduction
============

The incidence and mortality of lung cancer is on the rise worldwide ([@b1-mco-0-0-1763]) and is the leading cause of death among men and the second leading cause of cancer death among women all over the world ([@b2-mco-0-0-1763]). In China, it is estimated that more than 4 million cases of cancer and nearly 3 million cancer deaths occur ([@b3-mco-0-0-1763]). Most lung cancer patients were diagnosed as at advanced stages and were clinically inoperable. Conventional treatments including surgery, chemotherapy and radiotherapy for lung cancer have proven to be ineffective for late stages of lung cancer. The 5-year survival rate of lung cancer is poor ([@b4-mco-0-0-1763]). Early diagnosis and accurate prognosis analysis are important to improve the survival rate of lung cancer patients. Discovery of microRNAs (miRNAs/miRs) has opened up a new horizon for predicting the prognosis of lung cancer. Many cancer-associated miRNAs can predict the prognosis of lung cancer and can be targeted for treatment ([@b5-mco-0-0-1763]), but the results from individual experiments of the miRNAs are still inconsistent.

miRNAs are short noncoding RNAs that consist of 21--23 nucleotides in length, which participate in the process of translational repression or degradation of mRNA ([@b6-mco-0-0-1763]). Emerging studies showed that the expression levels of miRNAs in cancer were different from that in normal tissues. Besides, the specific expression signatures were correlated with prognosis of cancer, such as breast cancer, colorectal cancer and gastric cancer. According to the existing research results, a growing number of researchers found that different genes were related to the prognosis of lung cancer. miRNAs may play a key role in the pathogenesis of lung cancer and can be targets for potential therapeutics for the disease ([@b7-mco-0-0-1763],[@b8-mco-0-0-1763]). For example, it was reported that high levels of *miR-211* were associated with poor survival in human non-small cell lung cancer (NSCLC) patients. *miR-211* promotes tumor proliferation and invasion via regulating MxA expression in NSCLC, which suggested that manipulation of the level of *miR-211* may provide a novel therapy for NSCLC patients in the future ([@b9-mco-0-0-1763]). *miR-197* expression was associated with tumor size and identified as a novel independent predictor of unfavorable prognosis for NSCLC patients ([@b10-mco-0-0-1763]). *miR-638* levels were associated with the survival of NSCLC patients and may be also considered a potential independent predictor for NSCLC prognosis ([@b11-mco-0-0-1763]). The associations between miRNAs and lung cancers were reported in many meta-analyses ([@b12-mco-0-0-1763]--[@b14-mco-0-0-1763]), but the evaluation of the prognostic role of miRNAs in lung cancer has not been fully analyzed. In this report, we systematically performed a meta-analysis of miRNAs profiling with cancer stage, LNM and OS rate of the lung cancer patient.

Materials and methods
=====================

### Study selection and inclusion criteria

Literature in PubMed database was comprehensively searched (last updated search being February 1st, 2018). The publications were identified with a combination of the key words: miRNA, miRNAs, Micro RNA, RNA Micro, miRNA, Primary MicroRNA, Primary miRNA, pri-miRNA, pri miRNA, small temporal RNA, small stRNA, small temporal RNA, pre-miRNA, pre miRNA, lung neoplasms, lung neoplasia, lung neoplasias, lung tumors, lung benign neoplasms, lung benign neoplasm, lung benign malignancy, lung malignancies, lung cancer and lung cancers.

To be included in the meta-analysis, studies had to meet the following criteria: i) The subjects of studies were lung cancer patients diagnosed through pathology or cytology; ii) the studies aimed to investigate the relationship between miRNAs and lung cancer patients; iii) patients were grouped according to expression levels of miRNAs, which were measured in primary tumor tissues or adjacent normal tissue; iv) related clinical pathological characteristics were shown, such as tumor stages of cancers (T), lymph node metastasis (LNM), or distant metastasis (DM); v) available data contained information about the prognostic value of patients with survival outcomes, such as overall survival (OS)/recurrence-free survival (RFS)/event-free survival(EFS)/distant metastases-free survival (DMFS)/progression-free survival (PFS); vi) data contained hazard ratio (HR) or relative risk (RR) and corresponding 95% CI, directly or indirectly; and vii) full-text paper was available.

Studies were excluded if one of the following existed: i) Duplicate publications; ii) non-human study or non-clinical study or animal study or non-English study; iii) reviews, case reports, letters, editorials, and expert opinions; and iv) studies without available data or no complete text.

### Data extraction

For the eligible studies, data was extracted independently by two investigators (DY and SY). Disagreements were resolved by discussion with another investigator (WX or YZ). The following data was extracted: i) Publication information: The first author\'s name, the year of publication and the country of origin; ii) patients\' characteristic information: Number of participants, type of lung cancer, type of miRNAs, clinical tumor stage, and follow-up duration; iii) miRNA detection information: Tissue sample, method and cut-off values; iv) prognosis information: The number of patients with lymph nodes metastasis and different tumor stage; and v) survival analysis and multivariate analysis: ORs of miRNAs for LNM, HRs of miRNAs for OS and corresponding 95% Cl and P-values. This data was either obtained from the original article directly with sufficient data or via Engauge Digitizer version 4.1 to extract when only Kaplan-Meier curves were available.

Two investigators (YZ and WX) used the Newcastle-Ottawa Scale (NOS) to independently assess the quality of all the included studies. There were three major sections (selection, comparability and outcome) in NOS. The selection consisted of adequacy information of case definition, number of case in the research and representative miRNAs. The comparability contained miRNA exposure, detection method and cut-off values. The outcome included assessment results and adequate follow-up time. The highest score of NOS criteria was 8 with the lowest score being 0. The higher the score on this test is indicative of a better quality and a study with an NOS score equal to or more than 5 is considered to be of good quality. Finally, we used Begg\'s test to evaluate potential publication bias. The result pattern was not significantly impacted by removing a single study each time.

### Statistical analysis

The STATA software version 12.0 (StataCorp LP, College Station, TX, USA) was used for the following statistical analysis and to generate a forest plot to show the content of this statistical analysis. I^2^ statistics and P-values were used for investigating the heterogeneity among combined studies. The heterogeneity was regarded as significant when the I^2^ value \>50% or a P-value \<0.05 for Q test, while I^2^ values \<50% or P-value \>0.05 indicated that there was no significant heterogeneity, indicating that a random-effects model had been used to test heterogeneity.

When evaluating the association between miRNAs, prognosis, LNM and T, we used both HR/RR and 95% CI. Sensitivity analyses were used to test the effect of each study on pooled results. The potential publication bias was performed by Begg\'s test and funnel plots were used to show the results. P\<0.05 was considered to indicate a statistically significant difference. The biased risks of all the included studies were according to the basis for assessing the internal validity of the prognostic study and the recommendations on the biomarker research report ([@b15-mco-0-0-1763]--[@b17-mco-0-0-1763]).

Results
=======

### Characteristics of eligible studies, publication bias and sensitivity analysis

Our initial search of the database identified 231 publications. Two duplicate studies were excluded. We first carefully reviewed the titles and abstracts of each article, a total of 28 of them were excluded due to not containing full text, review articles, meta-analysis or not being in English. We then performed a detailed evaluation of each full text and 186 of them were further excluded due to being animal experiments, irrelevant clinical studies or without data available; therefore, only 15 articles were eligible for the final analysis ([@b10-mco-0-0-1763],[@b11-mco-0-0-1763],[@b18-mco-0-0-1763]--[@b30-mco-0-0-1763]). The process of study selection is presented in [Fig. 1](#f1-mco-0-0-1763){ref-type="fig"} and the main characteristics of the included articles are summarized in [Table I](#tI-mco-0-0-1763){ref-type="table"}.

All of the included studies are considered as high quality, as their NOS score was equal to or more than 5, while five of them scored 8 in the quality assessment. Quality assessment of eligible studies is shown in [Table II](#tII-mco-0-0-1763){ref-type="table"}.

We used Begg\'s test and funnel plots to evaluate potential publication bias. The shape of the funnel plot of the OS group was symmetrical (Begg\'s test, t=−0.78, P=0.447), indicating that no significant publication bias was observed by the Begg\'s test ([Fig. 2](#f2-mco-0-0-1763){ref-type="fig"}). Sensitivity analysis of the publications in the OS group is presented in [Fig. 3](#f3-mco-0-0-1763){ref-type="fig"}. The results pattern was not significantly impacted by removing a single study each time.

### Association between expression levels of miRNAs and LNM in lung cancer

Six studies with 740 lung cancer patients were included to assess the association between the expression levels of different miRNAs and LNM. Five miRNAs were evaluated in this group, including *miR-26b, miR-148α, miR-204, miR-638* and *miR-148b*. There was significant heterogeneity between the studies included (P\<1×10^−4^, I^2^=93.8%). The random-effects model was applied and *miR-148α* was investigated in two studies ([@b19-mco-0-0-1763],[@b22-mco-0-0-1763]). There were 150 patients who became LNM among 377 patients with high miRNA expression, with a percentage of 39.8%; but patients with low miRNA expression were more likely to become LNM as the percentage was 71.8%. Analysis showed that the pooled RR was 0.53 (95% CI: 0.46--0.61, P\<1×10^−4^), which indicated that low expression of miRNAs was predictive of LNM ([Fig. 4A](#f4-mco-0-0-1763){ref-type="fig"}).

### Association between miRNA levels and lung cancer T stages

Seven studies containing 1,031 patients were included to evaluate the relationship between miRNA level and tumor T stage. We divided T1 into a low T stage group and T2-4 into high a T stage group, according to T stage level (T1/2/3/4). Significant heterogeneity was found among the studies (P\<1×10^−4^, I^2^=79%) and a random-effects model study showed a pooled RR of 1.07 with a 95% CI of 0.94--1.22 (P=0.23), indicating that the expression of miRNAs might not be a direct predictor of T stage ([Fig. 4B](#f4-mco-0-0-1763){ref-type="fig"}).

### Association between the expression of miRNAs and OS of lung cancer patients

Thirteen studies of 1,536 lung cancer patients were included to assess the correlation between different miRNA expression levels and OS. Subgroup analysis was performed on the basis of the expression of miRNAs. Eight studies of 768 lung cancer patients reported the relationship between downregulated expression of different miRNAs and OS, including *miRNA-26b, miRNA-381, miRNA-146α, miRNA-148α, miRNA-204, miRNA-374α, miRNA-638* and *miRNA-148b*. There was no significant heterogeneity among the combined studies (P=0.434, I^2^=0%) by applying the random effects model ([@b31-mco-0-0-1763]). We found that low expression of these miRNAs was associated with shorter OS of lung cancer patients, according to the pooled HR of 0.59 with a 95% CI of 0.47--0.75, (P\<1×10^−4^). High expression of 8 miRNAs mentioned above increased the likelihood of survival. Five studies of 768 lung cancer patients reported the relationship between upregulated expression of different miRNAs and OS, including *miRNA-125b, miRNA-21, miRNA-141, miRNA-200c, miRNA-197, miRNA-41, miRNA-370, miRNA-376α, miRNA-192* and *miRNA-662*. There was significant heterogeneity among the combined studies (P=0.014, I^2^=60.2%). High expression of these 10 miRNAs was associated with poorer OS of lung cancer patients, according to the pooled HR of 1.76 with a 95% CI of 1.31--2.35 (P\<1×10^−4^) ([Fig. 4C](#f4-mco-0-0-1763){ref-type="fig"}). Only 2 studies included, had studied the association between the expression of miRNAs and disease-free survival (DFS) of lung cancers, while only 1 study accessed the association between the expression of miRNAs and DMFS of lung cancer patients. Since there were less than three of each type of study there was no test for association. All meta-analysis results are shown in [Table III](#tIII-mco-0-0-1763){ref-type="table"}.

Discussion
==========

Lung cancer is the most commonly diagnosed cancers among men and women. It is also the most commonly diagnosed cancer and the leading cause of cancer death in men aged 75 years or older ([@b3-mco-0-0-1763]). Although early diagnosis, targeting therapy and immunotherapy treatment of lung cancer have developed rapidly in recent years, a vast majority of lung cancers are still diagnosed at a late stage ([@b32-mco-0-0-1763]) and have poor prognosis. The 5-year survival rate is only approximately 10% and is one of the lowest among cancer patients ([@b33-mco-0-0-1763]). Finding new biomarkers can not only improve early diagnosis but also provide new targeting means after prognosis analysis. miRNAs have emerged as new regulators of cancer genomes and accumulating studies have found that many miRNAs are associated with the prognosis of lung cancer, especially NSCLC ([@b34-mco-0-0-1763],[@b35-mco-0-0-1763]).

On the one hand, there are few studies focus on the relationship between the same miRNA and lung cancer, so it is impossible for us to discuss. A meta-analysis is a statistical analysis that combines the results of multiple scientific studies. In our meta-analysis, we examined all evidences on the potential role of various miRNAs in lung cancer in order to systemically analyze the available clinical data. On the other hand, the targets and mechanism of miRNAs in lung cancer are still unclear, summarizing all the similar researches can provide us a direction in clinical work and improve our comprehension of potential intricate biological mechanism. We analyzed and evaluated the association between expression levels of multiple miRNAs and clinical prognosis for lung cancer patients, which laid a foundation for the diagnosis, prognosis evaluation and targeted therapy of lung cancer.

We found that high expression of *miR-125b, miR-21, miR-141, miR-200c, miR-197, miR-41, miR-370, miR-376α, miR-192* and *miR-662* resulted in a lower level of survival among patients. We also found that low levels of expression of *miR-26b, miR-381, miR-146α, miR-148α, miR-204, miR-374α, miR-638* and *miR-148b* also resulted in a lower level of survival among patients. Our analysis showed that high expression of miRNAs was correlated with LNM in lung cancer. We could not observe the relationships between the expression of various miRNAs and tumor stages, DMS or DMFS, which may be due to the samples size of this study.

miRNAs can regulate growth factors, target tumor suppression genes and other transcriptional factors to promote or inhibit the proliferation of cancer in humans. *miR-125b* may be associated with TGF-β to stimulate cancer growth and the potential activation of TGF-β with the possibility of playing a role in promoting cancer ([@b36-mco-0-0-1763]). *miR-21* is one of the most commonly observed aberrant miRNAs in human cancers and a large scale miRNA analysis of 540 samples from six different types of solid tumors showed that *miR-21* was the only miRNA that was upregulated in all cancer types ([@b37-mco-0-0-1763]). *miR-21* is believed to target many tumor suppressors to regulate epithelial-mesenchymal transition, invasion and metastasis in lung cancer ([@b38-mco-0-0-1763]). There is evidence that *miR-141* promoted the proliferation of non-small cell lung cancer cells by regulating the expression of PH domain leucine-rich-repeats protein phosphatase 1 and 2 (PHLPP1 and PHLPP2) ([@b39-mco-0-0-1763]). *miR-200c* was found to exert tumor-suppressive effects for NSCLC through the suppression of USP25 expression ([@b40-mco-0-0-1763]). *miRNA-197* acts as an oncogene downregulating p53 and FUS1 tumor suppressor gene expression ([@b41-mco-0-0-1763],[@b42-mco-0-0-1763]). It was also shown to be associated with brain metastasis in EGFR-mutant lung cancer ([@b43-mco-0-0-1763]). *miR-370* was reported to inhibit the progression of non-small cell lung cancer by downregulating the oncogene TRAF4 ([@b44-mco-0-0-1763]). *miR-376α* could suppress the proliferation and invasion of non-small-cell lung cancer by targeting c-Myc ([@b45-mco-0-0-1763]). *miR-192* was found to regulate chemo-resistance of lung adenocarcinoma for gemcitabine and cisplatin combined therapy by targeting Bcl-2 ([@b46-mco-0-0-1763]). *miR-662* may provide an alternative mechanism of downregulation of a tumor suppressor gene GDF10 that belongs to the TGF-β family ligands ([@b25-mco-0-0-1763]). *miR-26b* was shown to function as a critical regulator of tumor progression and carcinogenesis because it acts as either a tumor suppressor or an oncogene in various cancers ([@b29-mco-0-0-1763]). *miR-381* targeted IGF-1R to deactivate the protein kinase B (AKT) and extracellular signal-regulated kinase (ERK) signaling pathways ([@b47-mco-0-0-1763]). Overexpression of *miR-146α* significantly enhanced cell apoptosis, inhibiting cell viability and motility *in vitro* and *in vivo* and *miR-146α* could specially degrade the mRNA of cyclin J in the development of acquired drug resistance to DDP-based chemotherapy in NSCLC cells ([@b48-mco-0-0-1763]). Overexpression of *miRNA-148α* inhibited Wnt-1 protein expression in cancer cells. Knocking down Wnt-1 by siRNA had a similar effect to that of *miRNA-148α* overexpression on cell migration and invasion in lung cancer cells ([@b19-mco-0-0-1763]). *miR-148b* was reported to regulate radio-resistance of lung cancer cells by modulating the level of MLH1 expression ([@b49-mco-0-0-1763]). *miRNA-204* suppressed human non-small cell lung cancer by targeting activating transcription factor 2 (ATF2) ([@b50-mco-0-0-1763]). *miR-374α* had very significantly affected pathways of cell migration ([@b27-mco-0-0-1763]). Downregulation of *miRNA-638* promotes angiogenesis and growth of hepatocellular carcinoma by targeting VEGF ([@b51-mco-0-0-1763]).

Though the sample types were different from each other in the publications included in our analysis, we put them together for some reasons. Firstly, all the studies included in the paper used qPCR, allowing comparisons to be made between them. Secondly, it was reported that serum miRNAs have potential clinical value as tumor markers for screening NSCLC. Serum expression levels of *miR-125b* and *miR-22* in NSCLC patients were significantly higher than those with benign lung diseases and those in the healthy controls ([@b52-mco-0-0-1763]). It also reported that serum and plasma could be better mediums to measure miRNA compared to sputum and whole blood. When combining CT scanning with miRNA measured in serum or plasma, the sensitivity value increased ([@b35-mco-0-0-1763]). Last but not least, there is a continued need for the development of minimally-invasive, cost-effective and easy methods to diagnose lung cancer at an earlier, curable stage. The miRNA levels in plasma, serum and other biological fluids could be optimistic and promising markers in the future.

Several high-quality studies arouse us great interest before we drafted our study. Similar publications have been published looking into the value of miRs in lung cancer ([@b53-mco-0-0-1763]--[@b55-mco-0-0-1763]). Since the topic has been hot in recent research, we performed this analysis. Different from previous studies, we further evaluated the relationship between expression levels of multiple miRNAs and cancer stage and LNM for lung cancer patients. In our meta-analysis, we summarized and reviewed all the similar researches and identified that a few miRNAs could serve as a novel predictor for the prognosis of NSCLC. It also provided very useful resources for new therapeutic targets for the management of lung cancer in the future. However, we also understood that there had a number of limitations in our research. First, it was only based on the results of one database (PubMed) and some relevant studies might have been missed. Second, only 15 articles were included in this analysis and all of the cancer types were NSCLC. Third, though the detection method of miRNAs in all studies analyzed were reverse transcription qPCR, the kits, analytical methods and positive results evaluation criteria might have had variations which may have led to different experimental results. Fourth, the search language in this study was limited to English and other languages such as Chinese were not included, which might lead to an inevitable bias. Fifth, although no significant publication bias was found in the included studies, it still could not be completely avoided as positive results are more likely to be accepted while negative results are more likely to be rejected or not published. Sixth, the sample types were different from each other in the publications included in the analysis. These results were combined and therefore the overall determined conclusion of the study might not be widely applicable due to the inclusion of these different samples.

All in all, we have examined a substantial number of prognostic data about the association of various miRNAs and the survival of lung cancer patients. Our meta-analysis identified that a few miRNAs could serve as a novel predictor of prognosis in NSCLC. Larger studies are required to further confirm our observation and understanding of the roles of these miRNAs and their targets in cancer cells that can bring new therapeutic methods to NSCLC lung cancer treatment.
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![A flow diagram demonstrating the study selection process. Initially, a total of 231 records were identified on the database. Duplicate records were excluded to make sure each paper was only represented once within our set of records. A total of 28 records were excluded after reading the titles or the abstracts as these studies were reviews, meta-analyses, studies that were not in English or the full text was not available. After full-text reading of the studies that were not on human subjects, not clinical studies or without available data another 186 records were excluded. This process led to the identification of 15 studies eligible for systematic review.](mco-10-01-0067-g00){#f1-mco-0-0-1763}

![Begg\'s funnel plot of OS group. The meta-analysis for microRNA expression levels and OS in patients with lung cancer was analyzed using a funnel plot because it exceeded the pre-requisite of 10 studies. The y-axis represents the SE (logHR), which served as a measure of precision, where the higher the SE, the less precise the study. The HR has been plotted along the x-axis. The pattern of the study was symmetric which indicated that the bias of the study was small. SE, standard error; logHR, log hazard ratio; OS, overall survival.](mco-10-01-0067-g01){#f2-mco-0-0-1763}

![Sensitivity analysis of the publications in the overall survival group. Liu *et al*, 2012 ([@b23-mco-0-0-1763]) represents the data of miR-21. Liu *et al*, 2012 ([@b23-mco-0-0-1763])\* represents the data of *miR-141*. Liu *et al*, 2012 ([@b23-mco-0-0-1763])\*\* represents the data of *miR-200c*. Skrzypski *et al*, 2014 ([@b25-mco-0-0-1763]) represents the data of *miR-192*. Skrzypski *et al*, 2014 ([@b25-mco-0-0-1763])\* represents the data of *miR-662*. miR, microRNA; CI, confidence interval.](mco-10-01-0067-g02){#f3-mco-0-0-1763}

###### 

Forest plot analysis. (A) Forest plot of the LNM group. (B) Forest plot of the T group. (C) Forest plot of the OS group. Each plot A-C corresponds to the meta-analysis of a different group: (A) LNM, (B) T, and (C) OS. The effect size for the estimate of each study was presented as a grey square proportional in size to the weight of that study. The confidence interval around that effect size was presented as a horizontal line. The vertical line across these estimates represents HR=1 and any horizontal line crossing this vertical line represents a non-statistically significant result. The summary effect size was presented as a rhombus, the center of which represents the summary effect size and the width of which represents its CI. All meta-analyzed groups, apart from the T group (plot B), were statistically significantly associated with microRNAs. LNM, lymph node metastasis; RR, relative risk; CI, confidence interval; T, tumor stages of cancer; OS, overall survival; DR, downregulated; UR, upregulated.
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###### 

Characteristics of studies in the present meta-analysis.

  A, Study information                                                                                                                                                                                                                  
  -------------------------- ------------------------ ----------------------- ------------------- ------------------ ----------------------- --------------------------- ------------------ ------------------- ----------------------- -----------------------
  Mavridis *et al*, 2015     Greece                   197                     124                 Frozen tissue      qPCR                    X-tile algorithm            UR                 49                  75                      ([@b10-mco-0-0-1763])
  Wang *et al*, 2015         P.R. China               638                     189                 Serum              qPCR                    X-tile algorithm            DR                 112                 77                      ([@b11-mco-0-0-1763])
  Chen *et al*, 2013         P.R. China               146α                    101                 Tissue             qPCR                    Median                      DR                 0                   101                     ([@b18-mco-0-0-1763])
  Chen *et al*, 2017         P.R. China               148α                    159                 Tissue             qPCR                    Median                      DR                 73                  86                      ([@b19-mco-0-0-1763])
  Cui *et al*, 2013          P.R. China               125b                    260                 Serum              qPCR                    Median                      UR                 260                 0                       ([@b20-mco-0-0-1763])
  Guo *et al*, 2015          P.R. China               204                     126                 Plasma             qPCR                    Median                      DR                 66                  60                      ([@b21-mco-0-0-1763])
  Li *et al*, 2015           P.R. China               148α                    73                  Frozen tissue      qPCR                    Mean                        DR                 31                  42                      ([@b22-mco-0-0-1763])
  Liu *et al*, 2012          P.R. China               21                      70                  Frozen tissue      qPCR                    Mean                        UR                 48                  22                      ([@b23-mco-0-0-1763])
                                                      141                     70                                                                                                            49                  21                      
                                                      200c                    70                                                                                                            38                  32                      
  Nadal *et al*, 2014        USA                      411                     24                  Frozen tissue      qPCR                    Median                      UR                 24                  0                       ([@b24-mco-0-0-1763])
                                                      370                     33                  Frozen tissue      qPCR                    Median                      UR                 33                  0                       
                                                        376α                  34                  Frozen tissue      qPCR                    Median                      UR                 34                  0                       
  Skrzypski *et al*, 2014    Poland                   192                     223                 Frozen tissue      qPCR                    Median                      UR                 90                  133                     ([@b25-mco-0-0-1763])
                                                      662                     223                 Frozen tissue      qPCR                    Median                      UR                 90                  133                     
  Sun *et al*, 2013          P.R. China               150                     90                  Frozen tissue      qPCR                    Median                      UR                 0                   90                      ([@b26-mco-0-0-1763])
                                                      3940-5p                 90                  Frozen tissue      qPCR                    Median                                         0                   90                      
  Võsa *et al*, 2011         Estonia                  374α                    36                  Tissue             qPCR                    Median                      DR                 18                  18                      ([@b27-mco-0-0-1763])
  Wang *et al*, 2016         P.R. China               148b                    39                  Frozen tissue      qPCR                    Median                      DR                 18                  21                      ([@b28-mco-0-0-1763])
  Jiang *et al*, 2016        P.R. China               26b                     154                 Frozen tissue      qPCR                    Median                      DR                 77                  77                      ([@b29-mco-0-0-1763])
  Rothschild *et al*, 2012   Bern                     381                     18                  Tissue             qPCR                    Median                      DR                 3                   15                      ([@b30-mco-0-0-1763])
                                                                                                                                                                                                                                        
  **B, Statistics**                                                                                                                                                                                                                     
                                                                                                                                                                                                                                        
                             miRNA expression                                                                                                                                                                                           
                                                                                                                                                                                                                                        
  **Author, year**           **High with T2-4/3-4**   **Low with T2-4/3-4**   **High with LNM**   **Low with LNM**   **Survival analysis**   **Multivariate analysis**   **HR statistic**   **HR (95% CI)**     **Follow-up, months**   **Refs.**
                                                                                                                                                                                                                                        
  Mavridis *et al*, 2015     30                       38                                                             OS                      YES                         SC                 1.91 (1.75--3.19)   84                      ([@b10-mco-0-0-1763])
  Wang *et al*, 2015         73                       51                      87                  70                 OS                      YES                         SC                 0.61 (0.35--1.06)   60                      ([@b11-mco-0-0-1763])
  Chen *et al*, 2013         0                        73                      0                   66                 OS                      Unreported                  SC                 0.56 (0.21--1.51)   60                      ([@b18-mco-0-0-1763])
  Chen *et al*, 2017         58                       70                      27                  48                 OS                      YES                         SC                 0.85 (0.54--1.35)   120                     ([@b19-mco-0-0-1763])
  Cui *et al*, 2013          260                      0                                                              OS                      YES                         Rep                2.03 (1.14--3.05)   25                      ([@b20-mco-0-0-1763])
  Guo *et al*, 2015                                                           0                   49                 OS                      YES                         SC                 0.54 (0.31--0.94)   60                      ([@b21-mco-0-0-1763])
                                                                                                                     DFS                                                                    0.78 (0.44--1.36)                           
  Li *et al*, 2015           0                        37                      9                   30                 NA                      Unreported                                                         NA                      ([@b22-mco-0-0-1763])
  Liu *et al*, 2012          34                       0                       32                  0                  OS                      YES                         SC                 1.31 (0.42--3.03)   24                      ([@b23-mco-0-0-1763])
                             34                       0                       32                  0                                                                                         1.02 (0.37--2.82)                           
                             34                       0                       32                  0                                                                                         1.28 (0.04--2.53)                           
  Nadal *et al*, 2014        5                        0                                                              OS                      YES                         Rep                3.37 (1.42--8.0)    60                      ([@b24-mco-0-0-1763])
                                                                                                                     DFS                                                                    3.32 (1.61--6.88)                           
                             16                       0                                                              OS                      YES                         Rep                3.37 (1.42--8.0)    60                      
                                                                                                                     DFS                                                                    3.32 (1.61--6.88)                           
                             22                       0                                                              OS                      YES                         Rep                3.37 (1.42--8.0)    60                      
                                                                                                                     DFS                                                                    3.32 (1.61--6.88)                           
  Skrzypski *et al*, 2014    17                       24                                                             OS                      YES                         SC                 1.24 (1.06--1.45)   72                      ([@b25-mco-0-0-1763])
                                                                                                                     DMFS                                                                   1.12 (1.01--1.24)                           
                             17                       24                                                             OS                      YES                         SC                 2.58 (1.52--4.37)   72                      
                                                                                                                     DMFS                                                                   1.23 (1.09--1.38)                           
  Sun *et al*, 2013          0                        52                      0                   34                 NA                      YES                                                                NA                      ([@b26-mco-0-0-1763])
                             0                        52                      0                   34                                                                                                                                    
  Võsa *et al*, 2011                                                                                                 OS                      YES                         SC                 0.98 (0.16--5.88)   84                      ([@b27-mco-0-0-1763])
  Wang *et al*, 2016         8                        19                      9                   7                  OS                      YES                         SC                 0.86 (0.31--2.38)   60                      ([@b28-mco-0-0-1763])
  Jiang *et al*, 2016        27                       43                      18                  51                 OS                      YES                         SC                 0.61 (0.26--1.44)   60                      ([@b29-mco-0-0-1763])
  Rothschild *et al*, 2012                                                                                           OS                      Unreported                  SC                 0.37 (0.25--0.66)   35                      ([@b30-mco-0-0-1763])
                                                                                                                     EFS                                                                    0.48 (0.31--0.93)                           

'Total no.' refers to the number of studies included in the meta-analysis of each microRNA; HR, hazard ratio; 95 % CI; 95% confidence interval; I^2^ is a measure of between-study heterogeneity; LNM, lymph node metastasis; T, tumor stage of cancers; OS, overall survival; RFS, recurrence-free survival; EFS, event-free survival; DFS, disease-free survival; DMFS, distant metastases-free survival; NA, not available; qPCR, quantitative polymerase chain reaction; SC, survival curve; DR, downregulation; UR, upregulation.

###### 

Quality assessment of eligible studies (NOS).

                             Selection   Comparability   Outcome                           
  -------------------------- ----------- --------------- --------- --- --- --- --- --- --- -----------------------
  Mavridis *et al*, 2015     1           1               1         1   1   1   1   1   8   ([@b10-mco-0-0-1763])
  Wang *et al*, 2015         1           1               1         1   1   1   1   1   8   ([@b11-mco-0-0-1763])
  Chen *et al*, 2013         0           1               1         1   1   1   1   1   7   ([@b18-mco-0-0-1763])
  Chen *et al*, 2017         1           1               1         1   1   1   1   1   8   ([@b19-mco-0-0-1763])
  Cui *et al*, 2013          1           1               1         1   1   1   1   0   7   ([@b20-mco-0-0-1763])
  Guo *et al*, 2015          1           1               1         1   1   1   1   1   5   ([@b21-mco-0-0-1763])
  Li *et al*, 2015           0           1               1         1   1   1   0   0   5   ([@b22-mco-0-0-1763])
  Liu *et al*, 2012          1           1               1         1   1   1   1   0   7   ([@b23-mco-0-0-1763])
  Nadal *et al*, 2014        0           1               1         1   1   1   1   1   7   ([@b24-mco-0-0-1763])
  Skrzypski *et al*, 2014    1           1               1         1   1   1   1   1   8   ([@b25-mco-0-0-1763])
  Sun *et al*, 2013          1           1               1         1   1   1   0   0   6   ([@b26-mco-0-0-1763])
  Võsa *et al*, 2011         0           1               1         1   1   1   1   1   7   ([@b27-mco-0-0-1763])
  Wang *et al*, 2016         0           1               1         1   1   1   1   1   7   ([@b28-mco-0-0-1763])
  Jiang *et al*, 2016        1           1               1         1   1   1   1   1   8   ([@b29-mco-0-0-1763])
  Rothschild *et al*, 2012   0           0               1         1   1   1   1   1   6   ([@b30-mco-0-0-1763])

NOS, Newcastle-Ottawa Scale.

###### 

Results of meta-analysis.

  Outcomes   No. of studies   No. of patients   HR/OR/RR (95% CI)   P-value      Heterogeneity I^2^ (%)   Publication bias P-value
  ---------- ---------------- ----------------- ------------------- ------------ ------------------------ --------------------------
  LNM        6                740               0.53 (0.46--0.61)   \<1×10^−4^   93.8                     0.145
  T          7                1,031             1.07 (0.94--1.22)   0.23         79.0                     0.527
  OS (DR)    8                768               0.59 (0.47--0.75)   \<1×10^−4^   0.0                      0.447
  OS (UR)    5                768               1.76 (1.31--2.35)   \<1×10^−4^   60.2                     0.447

CI, confidence interval; HR, hazard ratio; OR, odds ratio; RR, relative risk; LNM, lymph node metastasis; T, tumor state of cancers; OS, overall survival; DR, downregulation; UR, upregulation.

[^1]: Contributed equally
